HRP20140621T1 - Sinteza neurostimulativnog piperazina - Google Patents

Sinteza neurostimulativnog piperazina Download PDF

Info

Publication number
HRP20140621T1
HRP20140621T1 HRP20140621AT HRP20140621T HRP20140621T1 HR P20140621 T1 HRP20140621 T1 HR P20140621T1 HR P20140621A T HRP20140621A T HR P20140621AT HR P20140621 T HRP20140621 T HR P20140621T HR P20140621 T1 HRP20140621 T1 HR P20140621T1
Authority
HR
Croatia
Prior art keywords
formula
image
compound
compound whose
alkyl
Prior art date
Application number
HRP20140621AT
Other languages
English (en)
Croatian (hr)
Inventor
Sripathy Venkatraman
Syed Mahmood
Bingidimi I. Mobele
Olga Lapina
Kellie Vercoe
Ying Li
Jonathan Salsbury
Mark Mclaws
Original Assignee
Neuralstem, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140621(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralstem, Inc. filed Critical Neuralstem, Inc.
Publication of HRP20140621T1 publication Critical patent/HRP20140621T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
HRP20140621AT 2009-08-24 2010-08-24 Sinteza neurostimulativnog piperazina HRP20140621T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23647709P 2009-08-24 2009-08-24
PCT/US2010/046537 WO2011028548A1 (en) 2009-08-24 2010-08-24 Synthesis of a neurostimulative piperazine

Publications (1)

Publication Number Publication Date
HRP20140621T1 true HRP20140621T1 (hr) 2014-11-21

Family

ID=43649584

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140621AT HRP20140621T1 (hr) 2009-08-24 2010-08-24 Sinteza neurostimulativnog piperazina

Country Status (22)

Country Link
US (2) US9278933B2 (enExample)
EP (1) EP2470182B1 (enExample)
JP (1) JP5727482B2 (enExample)
KR (1) KR101701362B1 (enExample)
CN (2) CN105693601A (enExample)
AU (1) AU2010289802C1 (enExample)
BR (1) BR112012004161B1 (enExample)
CA (1) CA2772080C (enExample)
CL (1) CL2012000493A1 (enExample)
DK (1) DK2470182T3 (enExample)
ES (1) ES2475721T3 (enExample)
HR (1) HRP20140621T1 (enExample)
IL (1) IL218298A (enExample)
IN (1) IN2012DN02370A (enExample)
MX (1) MX2012002335A (enExample)
NZ (1) NZ598891A (enExample)
PL (1) PL2470182T3 (enExample)
PT (1) PT2470182E (enExample)
RU (1) RU2567390C2 (enExample)
SG (1) SG178867A1 (enExample)
SI (1) SI2470182T1 (enExample)
WO (1) WO2011028548A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02370A (enExample) * 2009-08-24 2015-08-21 Neuralstem Inc
WO2018048927A1 (en) * 2016-09-12 2018-03-15 Neuralstem, Inc. Amelioration of neural deficits associated with diabetes
US20180104240A1 (en) * 2016-10-18 2018-04-19 Neuralstem, Inc. Amelioration of radiation-induced cognitive dysfunction
US10042957B2 (en) 2017-01-12 2018-08-07 Innovationdock, Inc. Devices and methods for implementing dynamic collaborative workflow systems
WO2018148733A1 (en) * 2017-02-13 2018-08-16 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
CN117377664A (zh) * 2020-12-23 2024-01-09 贝勒医学院 孤儿核受体tlx的小分子调节剂
JP2024520722A (ja) 2021-06-03 2024-05-24 オルト・ニューロサイエンス・インコーポレイテッド 不良な認知を有するうつ病患者の治療方法及びベンジルピペラジン-アミノピリジン剤の恩恵を受ける他の患者の選択
US12208096B2 (en) 2022-12-05 2025-01-28 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
AU2023391488A1 (en) 2022-12-05 2025-05-22 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent
US12233059B2 (en) 2022-12-05 2025-02-25 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175075B (hu) * 1977-06-30 1980-05-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija piperazidov piridin-karbonovoj kisloty
JPS54122283A (en) * 1978-03-13 1979-09-21 Sumitomo Chem Co Ltd Novel quinazoline derivative and its preparation
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE60330323D1 (de) * 2002-03-29 2010-01-14 Schering Corp Stereoselektive alkylierung von chirale 2-methyl-4-geschützte piperazinen
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
EP1576134B1 (en) * 2002-12-09 2013-03-06 Judith Kelleher-Andersson Method for discovering neurogenic agents
BRPI0414209B8 (pt) * 2003-09-09 2021-05-25 Hoffmann La Roche derivados de 1-(2-amino-benzol)-piperazina, seus processos de preparação e seu uso, e medicamento
EP1828165B1 (en) 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
US7754724B2 (en) * 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
AU2006329007A1 (en) * 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
IN2012DN02370A (enExample) * 2009-08-24 2015-08-21 Neuralstem Inc

Also Published As

Publication number Publication date
RU2012111227A (ru) 2013-10-10
HK1172844A1 (en) 2013-05-03
US9278933B2 (en) 2016-03-08
JP2013502462A (ja) 2013-01-24
BR112012004161A2 (pt) 2016-03-29
AU2010289802B2 (en) 2014-10-02
IL218298A0 (en) 2012-04-30
EP2470182A4 (en) 2013-04-24
EP2470182B1 (en) 2014-06-04
PL2470182T3 (pl) 2015-05-29
BR112012004161B1 (pt) 2020-04-07
AU2010289802C1 (en) 2015-04-16
MX2012002335A (es) 2012-07-04
US20160090358A1 (en) 2016-03-31
IL218298A (en) 2017-03-30
CL2012000493A1 (es) 2012-09-28
US20130005974A1 (en) 2013-01-03
EP2470182A1 (en) 2012-07-04
CN102711764A (zh) 2012-10-03
AU2010289802A1 (en) 2012-04-12
KR20120054642A (ko) 2012-05-30
NZ598891A (en) 2014-05-30
DK2470182T3 (da) 2014-07-21
ES2475721T3 (es) 2014-07-11
JP5727482B2 (ja) 2015-06-03
SI2470182T1 (sl) 2014-10-30
WO2011028548A1 (en) 2011-03-10
US9481649B2 (en) 2016-11-01
CN105693601A (zh) 2016-06-22
SG178867A1 (en) 2012-04-27
IN2012DN02370A (enExample) 2015-08-21
CA2772080A1 (en) 2011-03-10
KR101701362B1 (ko) 2017-02-01
CA2772080C (en) 2017-05-30
PT2470182E (pt) 2014-07-24
RU2567390C2 (ru) 2015-11-10

Similar Documents

Publication Publication Date Title
HRP20140621T1 (hr) Sinteza neurostimulativnog piperazina
HRP20201847T2 (hr) Postupak za pripremu spoja diariltiohidantoina
JP2012508235A5 (enExample)
PH12012502223A1 (en) Composition , method and use
TN2009000077A1 (en) Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX2009012082A (es) Compuestos de ariloazol-2-il cianoetilamino, metodo para prepararlos y metodo para utilizarlos.
EP3056486A3 (en) Process for preparing intermediates for antiviral compounds
EA201591277A1 (ru) Пирролобензодиазепины и их конъюгаты
IN2014MN02175A (enExample)
WO2012070069A3 (en) A process for preparation of albendazole
JP2010529994A5 (enExample)
MX352470B (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
HRP20121026T1 (hr) Postupak za dobivanje kaspofungina i njegovih intermedijera
MX352607B (es) Proceso para la preparacion de benzoxaboroles.
WO2014017938A3 (en) Process for the synthesis of substituted urea compounds
MY160882A (en) Biocidal composition and method
GB2480409A (en) Biocidal compositions comprising a phosphonium salt and a polymeric quaternary ammonium compound
WO2010080795A3 (en) Hydrogen peroxide complexes and their use in the cure system of anaerobic adhesives
IL200323A0 (en) Synthesis of glyt-1 inhibitors
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
WO2009131493A3 (ru) Производные 5-гидpoкcи-4-aминoмeтил-l-циклoгeкcил (или циклoгeптил)--3-aлкoкcикapбoнилиндoлoв, их фармацевтически приемлемые соли, обладающие противовирусной активностью, и способ их получения
JP2013522207A5 (enExample)
HRP20170776T1 (hr) Postupak za pripravu modulatora histaminskog h3 receptora
WO2007110649A3 (en) Process for the preparation of 2,6,9-trisubstituted purines